Thyroid Dysfunction Induced by Anti-PD-1 Therapy in Patients With Advanced Carcinoma
Completed
- Conditions
- Carcinoma
- Registration Number
- NCT05593744
- Lead Sponsor
- Qilu Hospital of Shandong University
- Brief Summary
In this study, we monitored patients with advanced malignant tumors who received anti-PD-1 therapy to observe the characteristic of anti-PD-1 therapy-induced thyroid dysfunction and its correlation with prognosis.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Eighteen years or older
- Confirmed diagnosis of malignancy
- Received anti-PD-1 therapy
Exclusion Criteria
- Thyroid malignancy or history of thyroid malignancy
- Thyroid dysfunction before anti-PD-1 therapies
- Previous ICIs treatment
- Less than 2 cycles of anti-PD-1 treatment
- No thyroid function monitoring during treatment
- Known pituitary disease
- Pregnancy.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Progression-free survival Through study completion, an average of 17 weeks The time between initiation of anti-PD-1 therapy and disease progression or death, whichever came first.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Qilu Hospital, Shandong University
🇨🇳Jinan, Shandong, China
Qilu Hospital, Shandong University🇨🇳Jinan, Shandong, China